Mayo Clinic researchers identify drug resistance factors for advanced prostate cancer

In a new study published in Molecular Cancer Research, Mayo Clinic researchers identified critical genomic changes in response to abiraterone acetate/prednisone, a standard treatment option for men with progressive, incurable and castration-resistant prostate cancer.

Brentuximab vedotin may improve overall survival in patients with Hodgkin Lymphoma

A study led by researchers from Mayo Clinic Comprehensive Cancer Center has found that the addition of brentuximab vedotin to standard chemotherapy treatment improves overall survival in patients with Hodgkin Lymphoma, when compared to the current standard of chemotherapy alone. Results of the research were presented by Stephen Ansell, M.D., Ph.D., at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO) in Chicago and were published today in the New England Journal of Medicine.

Mayo Clinic Cancer Center Patients, Executive Director Highlighted in American Association for Cancer Research Cancer Disparities Progress Report

The American Association for Cancer Research today released its Cancer Disparities Progress Report 2022. The publication aims to raise awareness of the enormous toll that cancer exacts on racial and ethnic minorities and other diverse and medically underserved populations in the United States while highlighting areas of recent progress in reducing cancer health disparities.